279 related articles for article (PubMed ID: 27062188)
21. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
22. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
Krause A; Machacek M; Lott D; Hurst N; Bruderer S; Dingemanse J
CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):477-485. PubMed ID: 28556581
[TBL] [Abstract][Full Text] [Related]
23. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.
Kunz C; Luedtke D; Unseld A; Hamilton A; Halabi A; Wein M; Formella S
Int J Chron Obstruct Pulmon Dis; 2016; 11():585-95. PubMed ID: 27051282
[TBL] [Abstract][Full Text] [Related]
25. Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles.
Luo SB; Gu EM; Chen YA; Zhou SC; Fan C; Xu RA
Pharm Biol; 2022 Dec; 60(1):1-8. PubMed ID: 34860644
[TBL] [Abstract][Full Text] [Related]
26. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
27. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
28. Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
Axelsen LN; Poggesi I; Rasschaert F; Perez Ruixo JJ; Bruderer S
Br J Clin Pharmacol; 2021 Jan; 87(1):119-128. PubMed ID: 32415684
[TBL] [Abstract][Full Text] [Related]
29. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Itou M; Fujita T; Inoue K; Uchida N; Takagaki T; Ishii D; Kakuyama H
J Clin Pharmacol; 2020 Oct; 60(10):1397-1403. PubMed ID: 32437025
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
32. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
Hoch M; Darpo B; Remenova T; Stoltz R; Zhou M; Kaufmann P; Bruderer S; Dingemanse J
Drug Des Devel Ther; 2015; 9():175-85. PubMed ID: 25552906
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
34. Selexipag: First Global Approval.
Scott LJ
Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
[TBL] [Abstract][Full Text] [Related]
35. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.
Peterson L; Marbury T; Marier J; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):518-23. PubMed ID: 24033615
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
Sardana M; Moll M; Farber HW
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
38. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
Preston RA; Marbury T; Balaratnam G; Green M; Dixon S; Lehrer-Graiwer J; Washington C
J Clin Pharmacol; 2021 Apr; 61(4):493-505. PubMed ID: 33084052
[TBL] [Abstract][Full Text] [Related]
40. Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study.
Tanabe N; Fukuda K; Matsubara H; Nakanishi N; Tahara N; Ikeda S; Kishi T; Satoh T; Hirata KI; Inoue T; Kimura H; Okano Y; Okazaki O; Sata M; Tsujino I; Ueno S; Yamada N; Yao A; Kuriyama T
Circ J; 2020 Sep; 84(10):1866-1874. PubMed ID: 32879152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]